Milrinone (Primacor)

Subscribe to Selected New Research on Milrinone

437 relevant articles (64 outcomes, 87 trials/studies) found for this Drug

Description: A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the ionotropic potency of amrinone.

Also Known As:

Primacor; Corotrop; Corotrope; Milrinone Lactate; Sanofi Brand of Milrinone Lactate; Sanofi Synthelabo Brand of Milrinone; Sanofi Synthelabo Brand of Milrinone Lactate; Sanofi Winthrop Brand of Milrinone Lactate; Win-47203; Lactate, Milrinone; Win 47203; Win47203; (3,4'-Bipyridine)-5-carbonitrile, 6-dihydro-2-methyl-6-oxo-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

6-ethyl-5-propionyl-1,2-dihydro-2-oxo-3-pyridine carbonitrile

SF 348

SF 349

WIN 63291

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

6-ethyl-5-propionyl-1,2-dihydro-2-oxo-3-pyridine carbonitrile

SF 348

SF 349

WIN 63291

Experts

1.	Sidi, A: 4 articles (03/2008 - 03/2006)
2.	Gheorghiade, Mihai: 4 articles (09/2005 - 03/2002)
3.	Lobato, E B: 3 articles (03/2008 - 03/2006)
4.	Kirby, D S: 3 articles (03/2008 - 03/2006)
5.	O'Connor, Christopher M: 3 articles (05/2005 - 03/2002)
6.	Califf, Robert M: 3 articles (05/2005 - 03/2002)
7.	Klodell, C: 2 articles (03/2008 - 03/2006)
8.	Beaver, T: 2 articles (03/2008 - 03/2006)
9.	Muehlschlegel, J D: 2 articles (03/2008 - 12/2006)
10.	Kirby, David S: 2 articles (01/2007 - 10/2004)

Related Diseases

1.	Heart Failure 09/01/1994 - "Milrinone is an inotropic and vasodilator agent proven to be effective in the treatment of heart failure" 01/01/1987 - "Milrinone, a potent positive inotropic and vasodilating agent, has shown promise in the clinical treatment of congestive heart failure, but significant controversy about its mechanism of action exists" 09/01/1983 - "Milrinone is a potent cardioactive agent which should be beneficial in the treatment of acute and chronic congestive heart failure." 08/01/2000 - "Although phosphodiesterase 3 (PDE3) activity is abundant in human cardiovascular tissues, and acute PDE3 inhibition, with agents such as milrinone, was beneficial in heart failure patients, prolonged treatments were associated with time-dependent reductions in hemodynamic effects and increased mortality" 02/01/1993 - "Improved hemodynamic effects and the good safety/acceptability of the drug indicate that milrinone is a treatment of choice in cardiac failure." Order ALL the reference details at left...
2.	Pulmonary Hypertension (Ayerza Syndrome) 04/01/2000 - "CONCLUSIONS: We conclude that milrinone is effective in the management of pulmonary hypertension following CPB in children who underwent TOF repair." 09/01/2000 - "PURPOSE: The purpose of this study was to investigate whether the effect of milrinone on platelet aggregation was related to the selectivity of vasodilation vasculature in a swine model with PH. MATERIALS AND METHODS: To induce pulmonary hypertension, we injected two sets of acid-washed glass beads in 15 swine, which were divided into two groups (those receiving milrinone or not) and compared with each other" 01/01/1991 - "Further studies are needed to resolve the pulmonary vasodilatory effect of milrinone in dogs with pulmonary hypertension." 01/01/1991 - "The pulmonary hypertension dogs were divided into three groups: a) group E (n = 6) received embolization only, as control; b) group L (n = 6) received low-dose milrinone; and c) group H (n = 6) received high-dose milrinone, equivalent to the preliminary study group" 11/01/2008 - "Milrinone, a phosphodiesterase type 3 (PDE3) inhibitor, can also reduce PVR for postoperative patients with pulmonary hypertension" Order ALL the reference details at left...
3.	Ischemia 06/01/1991 - "Control ergometry revealed ischemia; however, during exercise with intravenous milrinone, ischemia was eliminated" 07/01/1999 - "To determine the role of beta adrenergic stimulation before ischemia, a dose-response study was undertaken with isoprotelenol and milrinone at 37 degrees C" 03/01/2008 - "CONCLUSION: We demonstrated that the pre-emptive administration of milrinone before ischemia was associated with less ischemic hemodynamic effects, without worsening the ischemic metabolic process" 03/01/2008 - "RESULTS: During ischemia, occlusion produced significant depression in LV dP/dT, Emax and concomitant elevation of LVEDP that persisted over early reperfusion in groups not treated with milrinone" 12/01/2006 - "CONCLUSION: The demonstrated improvement of hepatic microcirculation is certainly derived from milrinone induced cell protection in ischemia reperfusion of the liver" Order ALL the reference details at left...
4.	Hypotension (Low Blood Pressure) 06/01/2006 - "Infants who received milrinone did not develop systemic hypotension; in fact, there was a nonsignificant trend toward improved blood pressure" 02/01/2007 - "Systemic arterial hypotension and vasopressor requirements with milrinone use at inotropic doses were not observed at the doses used for the study" 12/01/2006 - "Compared to the intravenous administration, inhaled milrinone has been shown to reduce pulmonary artery pressure without systemic hypotension" 07/01/2005 - "RESULTS: Inhaled milrinone caused less hypotension ( P < .05), a lesser decrease in peripheral vascular resistances ( P < .01), and a lower heart rate ( P < .05) than intravenous milrinone" 08/01/2002 - "A common side effect of milrinone is hypotension from the peripheral vasodilation" Order ALL the reference details at left...
5.	Shock 03/01/1999 - "These data suggest that the administration of milrinone for the shock patients after cardiac surgery showed safe and that the continuous intravenous infusion of 0.5 microgram/kg/min without bolus loading showed effective for the recovery of the peripheral circulation." 03/01/1999 - "The effect of milrinone in the 16 postoperative shock patients of cardiovascular surgery was studied" 03/01/1999 - "The effect of milrinone for the shock patients after cardiac surgery]" 07/01/2008 - "CONCLUSIONS: When used to treat shock in newborn piglets with hypoxia-reoxygenation, milrinone improved cardiac output and carotid flow while maintaining systemic blood pressure" 11/01/2002 - "A higher dose of norepinephrine and milrinone were required to maintain blood pressure and cardiac output in SIELI and ARF/shock patients than preoperative controls (all p values less than 0.005)" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Amrinone (Amrinon)
2.	Dobutamine
3.	Brain Natriuretic Peptide (Natrecor)
4.	Nitroprusside (Sodium Nitroprusside)
5.	Phosphodiesterase Inhibitors
6.	M-2 protocol (M 2)
7.	Vasodilator Agents (Vasodilators)
8.	Type 3 Cyclic Nucleotide Phosphodiesterases
9.	Dopamine (Intropin)
10.	Metoprolol (Lopressor)

Related Therapies and Procedures

1.	Cardiopulmonary Bypass (Heart-Lung Bypass)
2.	Off-Pump Coronary Artery Bypass (Coronary Artery Bypass, Off Pump)
3.	Heart Transplantation (Grafting, Heart)
4.	Drug Therapy (Chemotherapy)
5.	Aftercare (After-Treatment)

Best Treatments:
Research Summary Report
on Heart Failure

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2626 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>